Best GLP-1 Providers in Kansas (2026)

See by medication

Looking for a specific GLP-1? Browse Kansas providers by drug.

About GLP-1s in Kansas

Kansas allows telehealth GLP-1 prescriptions. KanCare Medicaid covers GLP-1s only for type 2 diabetes diagnosis.

• •Kansas's adult obesity rate is 34.4%
• •KanCare Medicaid restricts GLP-1 coverage to diabetes
• •Compounded semaglutide is available via telehealth statewide

Top Cities for GLP-1 Treatment in Kansas

Telehealth providers ship to all Kansas addresses, but demand is highest in these metro areas:

Prefer an in-person clinic? Browse the Kansas GLP-1 clinic directory →

GLP-1 Care Access in Kansas: The Numbers

Kansas has 254 NPI-registered in-person weight-management clinics across 61 cities — 2 with an obesity-medicine taxonomy, 89 endocrinology, and 163 bariatric — alongside 96 telehealth programs that ship to Kansas addresses. The cheapest verified ongoing compounded semaglutide price available to Kansas residents is $65/mo (tirzepatide: $104/mo). Full methodology and the 50-state table: GLP-1 care access by state.

Insurance & Medicaid in Kansas

In Q1 2026, Kansas Medicaid reimbursed approximately $9,495,187 across 8,638 GLP-1 prescriptions (all covered indications, gross before rebates — federal SDUD data; full state series here).

Most insurance plans in Kansas cover GLP-1s for type 2 diabetes (Ozempic, Mounjaro), but coverage for obesity-only indications (Wegovy, Zepbound) is much more limited and often requires prior authorization. If your insurance won't cover brand-name GLP-1s, compounded semaglutide through telehealth is typically the most affordable option at around $189/mo.

For the exact criteria, drug list, and appeal process, read our Kansas Medicaid GLP-1 coverage & prior-authorization guide. For coverage backdoors, Zepbound is FDA-approved for obstructive sleep apnea, and Wegovy for kidney and cardiovascular indications, which some plans cover even when they exclude weight-loss-only use.

Obesity in Kansas

According to CDC data, 34.4% of Kansas adults have obesity (BMI of 30 or higher). This places Kansas at #14 out of 50 states. Access to GLP-1 medications like semaglutide and tirzepatide has expanded significantly through telehealth, helping Kansas residents get clinically supervised weight loss treatment from home.

To choose a medication, compare the clinical-trial results behind each drug, see our best semaglutide and tirzepatide provider rankings, or track the next-generation GLP-1 pipeline.

Frequently Asked Questions